B. Metzler seel. Sohn & Co. AG Buys Shares of 41,753 Edwards Lifesciences Corporation $EW

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 41,753 Edwards Lifesciences shares in the second quarter, worth approximately $3.8 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds producing a consensus “Moderate Buy” rating and an average price target of $100.27.
• Edwards Lifesciences beat quarterly expectations, reporting $0.78 in EPS on $1.74 billion in revenue, while revenue increased 13.6% year over year. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77.

B. Metzler seel. Sohn & Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,753 shares of the medical research company's stock, valued at approximately $3,777,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. TrinityBridge Ltd bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $27,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter valued at about $26,000. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the first quarter valued at about $25,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $27,000. Finally, JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $25,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on EW shares. Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Leerink Partners upgraded Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Barclays reiterated an "overweight" rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Finally, TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The company has a 50-day simple moving average of $89.21 and a two-hundred day simple moving average of $84.67. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company's stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company's stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source